Formulation and Delivery Technologies for mRNA Vaccines
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: closed (20 October 2022) | Viewed by 270
Special Issue Editor
Interests: vaccine adjuvants and delivery platforms
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The recent Covid-19 pandemic prompted the development of mRNA vaccines with the advantage of fast production in large scales. Two mRNA vaccines (Pfizer BNT162b2 and Moderna mRNA-1273) were developed in an unprecedented speed that showed more than 90% protective efficacy. Lipid nanoparticles play a crucial role in protection of mRNA from degradation and facilitation of intracellular delivery. Although currently approved mRNA vaccines contain no adjuvants, formulation of mRNA vaccines with new or traditional adjuvants may further enhance its efficacy. Currently approved mRNA vaccines are mainly administered by needle injection. Needle-free delivery technologies may relieve the pain and increase its acceptance rate. Besides infectious diseases, mRNA vaccines also hold a great promise to induce potent anti-tumor immunity. This special issue will focus on formulation and delivery technologies for mRNA vaccines against infectious diseases and cancer. Research articles, reviews, communications are all welcome.
Dr. Xinyuan Chen
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- mRNA vaccine
- lipid nanoparticle
- infectious disease
- cancer
- formulation
- delivery technologies
- adjuvants
